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Interleukin-1 receptor antagonist: friend or foe to the heart?
Interleukin 1β (IL-1β) is a potent proinﬂ ammatory 
cytokine that is implicated in development of chronic 
inﬂ ammatory disorders such as rheumatoid arthritis, but 
also cardiovascular diseases and type 2 diabetes.1 IL-1β 
signaling is blocked by IL-1 receptor antagonist (IL-1Ra), 
a natura lly occurring regulator of interleukin 1 (IL-1) 
cytokines. IL-1Ra binds to the IL-1 receptor and thereby 
prevents binding of both IL-1a and IL-1b, which are 
related cytokines but encoded by distinct genes.2 On 
the basis of preclinical, clinical and epidemiological 
studies,3–5 inhibition of the IL-1 pathway has been 
postulated to prevent cardiometabolic diseases.
In The Lancet Diabetes & Endocrinology, the Interleukin-1 
Genetics Consortium6 investigated cardiometabolic 
eﬀ ects of a genetic score derived from two single-
nucleotide polymorphisms (SNPs) located upstream 
of the IL1RN gene, which encodes IL-1Ra. The IL-1Ra-
raising alleles were associated with lower systemic 
concentrations of interleukin 6 and C-reactive protein, 
and lower odds of rheumatoid arthritis than non-IL-1Ra-
raising alleles. However, the investigators report per-
allele increased odds of coronary disease (mainly deﬁ ned 
as myocardial infarction and other major coronary 
events) and abdominal aortic aneurysm, whereas 
there were no such associations with ischaemic stroke 
and type 2 diabetes. The genetic score was also linked 
with increased concentrations of LDL cholesterol, total 
cholesterol, and triglycerides. A lifelong increase in LDL 
cholesterol was estimated by the investigators to explain 
20–40% of the excess cardiovascular risk conferred by 
genetic upregulation of IL-1Ra.
The Interleukin-1 Genetics Consortium is to be 
commended for their well-designed investigation to 
predict clinically relevant beneﬁ cial and adverse eﬀ ects 
of inhibition of a crucial proinﬂ ammatory pathway. The 
main ﬁ nding with respect to increased cardiovascular 
risk caused by genetically raised IL-1Ra concentrations 
seems counterintuitive and therefore merits a few 
comments. Several hypotheses seem possible to explain 
which mechanisms could underlie this association. 
First, IL-1Ra might have harmful cardiovascular eﬀ ects 
of its own. To the best of our knowledge, binding 
of IL-1Ra to the IL-1 receptor does not trigger any 
downstream signalling and no studies support this 
hypothesis. 
Second, physiological IL-1Ra upregulation could 
be a protective response to concomitant increases 
in activities of IL-1α or IL-1β that mediate increased 
cardiovascular risk. We and others have previously 
shown increased IL-1Ra concentrations in the circulation 
in individuals who subsequently developed type 2 
diabetes,7 which was interpreted as a futile attempt 
by the body to counter-regulate diabetogenic stimuli. 
However, we also noted in a meta-analysis that genetic 
upregulation of IL-1Ra was associated with decreased 
fasting insulin concentrations.8 This last ﬁ nding argues 
for beneﬁ cial metabolic eﬀ ects of lifelong increased 
IL-1Ra concentrations, and why this ﬁ nding was not 
replicated in this study remains to be shown. Eventually, 
this second hypothesis could only be corroborated 
by joint measurements of IL-1Ra concentration and 
activities of crucial cytokines of the IL-1 family.  
Third, IL-1α or IL-1β, or both, could have beneﬁ cial 
cardiovascular eﬀ ects that are prevented by IL-1Ra. IL-1α 
is constitutively expressed by many cell types and does 
not only exert inﬂ ammation-related functions, but 
also acts as an autocrine growth factor.2 Findings from 
at least one study of an IL-1 receptor-deﬁ cient mouse9 
showed cardioprotective eﬀ ects of IL-1 signalling in 
advanced atherosclerosis. 
Fourth, both SNPs on which the genetic IL-1Ra score 
was based might have pleiotropic eﬀ ects beyond 
regulation of IL-1Ra. The investigators did not ﬁ nd 
evidence for eﬀ ects of either SNP on expression of 
genes with transcription start sites within 1 Mb of 
the respective SNP in selected tissues. However, the 
possibility that these SNPs have additional eﬀ ects on 
more distant genes or in tissues not tested in the study 
(eg, leucocytes or hepatocytes) cannot be ruled out.
One general diﬃ  culty in interpretation of the data is 
the fact that the IL-1 system is mainly regulated at the 
protein level.1,2 Immunological and metabolic triggers 
activate protein complexes called inﬂ ammasomes 
that activate IL-1β. Unfortunately, appropriate genetic 
methods are not available to separately assess IL-1α 
or IL-1β activity or, as the investigators correctly 
emphasise, their selective inhibition.
With respect to clinical implications, the potential 
cardiovascular side-eﬀ ects of IL-1-targeting approaches 
should be monitored closely. However, data probably 
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cannot be generalised to approaches selectively 
inhibiting either IL-1α or IL-1β using monoclonal 
antibodies. The Canakinumab Anti-inﬂ ammatory 
Thrombosis Outcomes Study (CANTOS)4 will clearly 
answer the question of whether inhibition of IL-1β 
aﬀ ects cardiovascular risk factors and outcomes in 
patients with a history of cardiovascular events.
To shed additional light on the causality between 
regulation of the IL-1 system and cardiovascular risk, 
the distinct eﬀ ects of IL-1α and IL-1β in the diﬀ erent 
stages of atherogenesis need to be better understood. 
Findings from preclinical studies suggest that both 
cytokines have partly independent contributions 
in this context.10 Furthermore, despite the wealth 
of data provided by this comprehensive study, the 
mechanistic link between IL-1Ra and cardiovascular 
risk remains incompletely understood. On one hand, 
the provocative results should stimulate further 
research addressing the link between the IL-1 system 
and regulation of lipid concentrations. On the other, 
the absence of association between the genetic score 
and several subclinical cardiovascular phenotypes 
(carotid intima-media thickness, carotid plaque, 
and carotid-femoral pulse wave velocity) argues for 
further research to delineate the potential contribution 
of IL-1 signalling to the complex development of 
cardiovascular disorders.  
*Christian Herder, Marc Y Donath
Institute for Clinical Diabetology, German Diabetes Center, Leibniz 
Center for Diabetes Research at Heinrich Heine University 
Düsseldorf, 40225 Düsseldorf, Germany, and German Center for 
Diabetes Research, Düsseldorf Partner Site, Germany (CH); and 
Endocrinology, Diabetes and Metabolism, University Hospital 
Basel, Basel, Switzerland (MYD)
christian.herder@ddz.uni-duesseldorf.de 
We declare no competing interests.
Copyright © Herder et al. Open Access article distributed under the terms of CC BY.
1 Dinarello CA. Interleukin-1 in the pathogenesis and treatment of 
inﬂ ammatory diseases. Blood 2011; 117: 3720–32.
2 Dinarello CA. Immunological and inﬂ ammatory functions of the 
interleukin-1 family. Annu Rev Immunol 2009; 27: 519–50.
3 Fearon WF, Fearon DT. Inﬂ ammation and cardiovascular disease. Role of 
the interleukin-1 receptor antagonist. Circulation 2008; 117: 2577–79.
4 Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the 
prevention of recurrent cardiovascular events: rationale and design of the 
Canakinumab Anti-inﬂ ammatory Thrombosis Outcomes Study (CANTOS). 
Am Heart J 2011; 162: 597–605.
5 Donath MY. Targeting inﬂ ammation in the treatment of type 2 diabetes: 
time to start. Nat Rev Drug Discov 2014; 13: 465–76.
6 The Interleukin-1 Genetics Consortium. Cardiometabolic eﬀ ects of genetic 
upregulation of the interleukin 1 receptor antagonist: a mendelian 
randomisation analysis. Lancet Diabetes Endocrinol 2015; published online 
Feb 26. http://dx.doi.org/10.1016/S2213-8587(15)00034-0.
7 Herder C, Carstensen M, Ouwens DM. Anti-inﬂ ammatory cytokines and risk 
of type 2 diabetes. Diabetes Obes Metab 2013; 15 (suppl 3): 39–50.
8 Herder C, Nuotio ML, Shah S, et al. Genetic determinants of circulating 
interleukin-1 receptor antagonist levels and their association with glycemic 
traits. Diabetes 2014; 63: 4343–59.
9 Alexander MR, Moehle CW, Johnson JL, et al. Genetic inactivation of IL-1 
signaling enhances atherosclerotic plaque instability and reduces outward 
vessel remodeling in advanced atherosclerosis in mice. J Clin Invest 2012; 
122: 70–79.
10 Freigang S, Ampenberger F, Weiss A, et al. Fatty acid-induced mitochondrial 
uncoupling elicits inﬂ ammasome-independent IL-1α and sterile vascular 
inﬂ ammation in atherosclerosis. Nat Immunol 2013; 14: 1045–53.
Published Online
March 6, 2015
http://dx.doi.org/10.1016/ 
S2213-8587(15)00003-0
See Articles page 254 
Do
rli
ng
 K
in
de
rs
le
y/
UI
G/
 S
cie
nc
e 
Ph
ot
o 
Li
br
ar
y 
To mix or to separate: that is the question
Asia is at the epicentre of the recent worldwide 
epidemic of diabetes. Rapid changes in lifestyle with 
increasing calorie intake and decreased physical activity 
make some Asian people more susceptible to type 2 
diabetes. Compared with their western counterparts, 
Asian patients with type 2 diabetes are characterised 
by a lower BMI, increased visceral adiposity, decreased 
β-cell function, and relatively lower insulin resistance.1 
Diﬀ erent genetic make-ups and environmental factors 
might explain the discrepancies in these phenotypes 
of type 2 diabetes.1 Another clinically important 
characteristic of Asian patients with type 2 diabetes 
is marked postprandial hyperglycaemia during a 
standard oral glucose tolerance test.2 Because isolated 
postprandial hyperglycaemia is common in Asians,2 
diagnosis of type 2 diabetes might be delayed to a later 
stage when β-cell function is already compromised. 
Additionally, the staple food of most Asian people is 
rice and other carbohydrate-rich foods, which might 
exacerbate postprandial hyperglycaemia if diabetes 
is present. Therefore, a customised glucose-lowering 
strategy that eﬀ ectively addresses postprandial 
hyperglycaemia is necessary for Asian patients with 
type 2 diabetes. 
Basal insulin is generally recommended for patients 
with type 2 diabetes who are inadequately controlled 
with oral antidiabetic medications.3 If basal insulin is 
not suﬃ  cient to achieve glycaemic control, sequential 
addition of prandial rapid-acting insulin before 
main meals is recommended.3 Premixed insulin, 
which consists of basal and prandial insulin, can be 
used instead of basal insulin as starter insulin.4 In 
